• To evaluate the disease-modifying efficacy, safety and tolerability of cindunistat/SD-6010 50 mg and 200 mg QD compared to placebo in patients with symptomatic knee OA
• Primary endpoint: rate of radiographic JSN -Modified Lyon-Schuss X-rays at BL, 1 and 2 years -minJSW in medial TF compartment using DIA software 
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Conclusions
• Cindunistat was generally safe and well tolerated in this OA population
• Cindunistat was not superior to placebo in the primary endpoint, rate of JSN, in subjects with knee OA -During the first year of treatment, subjects with KLG2 had a slower rate of JSN -This early improvement was not sustained at 2 years -iNOS inhibition did not slow OA progression in subjects with KLG3
• The observed early effect on JSN in subjects with mild OA supports the role of iNOS in OA pathogenic mechanisms
• Alternative biochemical catabolic pathways may have overcome the effects of nitric oxide inhibition alone
• In more severe OA, biomechanical factors may not be amenable to iNOS inhibition 18| It all starts here.
Additional Thoughts
• At some point in the progression of OA, joint tissue deterioration may not be reversible through inhibition of iNOS -We attempted to select patients with less aberrant biomechanics (no valgus and only mild varus), although patients were overweight and obese
• Certain pathophysiological pathways, such as the iNOS-NO pathway, may be more relevant targets for pharmacological intervention early in disease -Other DMOAD studies suggest reduced disease progression after 1-year but lost after 2, or improvement in less severe OA
• No systematic measure of changes by MRI
• The current method of staging severity for clinical trials may be insufficient to adequately identify suitable candidates
• Research efforts must continue to validate biomarkers to improve patient selection and the detection of structure modification, particularly for patients with early OA where the potential for slowing progression is greater 19| It all starts here.
• Demonstration of structure modification in OA must be related to clinical benefit -By the time an OA joint becomes symptomatic, damage may already have progressed beyond the capability of pharmacological modification, making DMOAD trials in patients presenting with OA pain inappropriate -Limitation of our study was access to standard-of-care which may have introduced noise and/or bias
• Altered mechanics in even radiographic "mild-to-moderate" OA might be overwhelming and may not be effectively altered with a pharmacological or biological structure-modifying agent -iNOS may have been too limited a target to retard progression of OA in established disease -A broad-based target may be more successful -Evidence from surgical approaches to OA, (i.e., distraction procedures, osteotomy) indicate that joints can heal when biomechanical stresses are normalised 20| It all starts here.
• Discovering New Therapeutic Uses for Existing Molecules -A collaborative program that will match academic researchers with molecules form pharmaceutical companies to help scientists explore new treatments for patients -Provide access to molecules that are no longer in development due to a lack of efficacy in their primary indication(s) 
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